Artivion, Inc. (AORT)
NYSE: AORT · Real-Time Price · USD
32.06
+1.14 (3.69%)
At close: Aug 4, 2025, 4:00 PM
32.06
0.00 (0.00%)
After-hours: Aug 4, 2025, 7:00 PM EDT

Company Description

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.

The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products.

It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.

In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers.

It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons.

The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022.

Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Artivion, Inc.
Artivion logo
CountryUnited States
Founded1984
IPO DateFeb 11, 1993
IndustryMedical Devices
SectorHealthcare
Employees1,600
CEOJames Mackin

Contact Details

Address:
1655 Roberts Boulevard NW
Kennesaw, Georgia 30144
United States
Phone770 419 3355
Websiteartivion.com

Stock Details

Ticker SymbolAORT
ExchangeNYSE
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000784199
CUSIP Number228903100
ISIN NumberUS2289031005
Employer ID59-2417093
SIC Code3841

Key Executives

NamePosition
James Patrick MackinChairman, President and Chief Executive Officer
Lance A. Berry CPAExecutive Vice President of Finance and Chief Financial Officer
Jean F. Holloway Esq.Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
John E. DavisSenior Vice President and Chief Commercial Officer
Dr. Marshall S. Stanton M.D.Senior Vice President of Clinical Research and Chief Medical Officer
Florian TyrsVice President of Global Operations
Amy D. Horton CPAVice President and Chief Accounting Officer
Matthew A. GetzVice President of Human Resources and Chief Human Resources Officer
Jason D. AsperSenior Vice President and Chief Strategy and Digital Officer
Dr. Robert C. Thomson Ph.D.Vice President of Research and Development

Latest SEC Filings

DateTypeTitle
Jul 21, 2025SCHEDULE 13G/AFiling
Jun 17, 2025144Filing
Jun 13, 2025144Filing
May 29, 20258-KCurrent Report
May 27, 2025144Filing
May 23, 2025144Filing
May 21, 2025144Filing
May 21, 2025144Filing
May 19, 2025SDForm - SD
May 16, 20258-KCurrent Report